Personalized Pre-Surgery breast cancer treatment shows promise in small trial
NCT ID NCT05101564
First seen Jan 30, 2026 · Last updated May 07, 2026 · Updated 15 times
Summary
This study tested whether adding a drug that targets specific genetic changes found in some breast tumors could slow tumor growth more than standard hormone therapy alone. The trial included 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal was to see how well these targeted therapies work based on each tumor's unique genetic makeup.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
Explore the condition pages connected to this study.